Background: Within the EU, some of the challenges and perceived risks now facing medical device (MD) developers result from changes in the regulatory framework, emphasizing safety. Therefore, medical technology companies must adopt stricter quality assurance measures so that individual devices can be speedily tracked and retrieved in emergency situations. Objectives: We highlight the challenges and risks faced by the European medical devices industry, particularly those faced by SMEs in the Czech Republic. We address two important research questions: Q1. Do advantages from increased regulation outweigh the additional expenses? Q2. As many MD developers are SMEs, will the new regulatory regime result in some of those companies going out o...
Context Recent debates and events have brought into question the effectiveness of existing regulator...
Medical devices have historically been less regulated than their drug and biologic counterparts. A b...
Are FDA premarket trials on new drugs and medical devices excessive and do they inhibit consumer acc...
Background Up until 2017, medical devices were placed on the European Union’s (EU) single market in...
Concerns have been raised over the quality of evidence on the performance of medical artificial inte...
Following a series of major scandals over the past two decades, the medical device industry is now u...
Background: The background of this study is the change in regulatory frame-works for medical devices...
Since 2010, two significant international regulations regarding medical device development have come...
This study explores new product development in a strict regulatory and historically secretive enviro...
The EU medical device (MD) regulatory structure has changed from Directives to Regulations to ascer...
The high quality of public health improves not only healthy life expectancy, but also the productivi...
ABSTRACT Introduction: Favoring innovation by making timely medical technology available to people ...
Balancing acceptable risks and early release of products for new treatments in patient care with the...
Imagine a device that could help identify skin cancer by examining moles underneath a patient’s skin...
ObjectivesTo identify the potential opportunities and risks around future UK regulatory reform of me...
Context Recent debates and events have brought into question the effectiveness of existing regulator...
Medical devices have historically been less regulated than their drug and biologic counterparts. A b...
Are FDA premarket trials on new drugs and medical devices excessive and do they inhibit consumer acc...
Background Up until 2017, medical devices were placed on the European Union’s (EU) single market in...
Concerns have been raised over the quality of evidence on the performance of medical artificial inte...
Following a series of major scandals over the past two decades, the medical device industry is now u...
Background: The background of this study is the change in regulatory frame-works for medical devices...
Since 2010, two significant international regulations regarding medical device development have come...
This study explores new product development in a strict regulatory and historically secretive enviro...
The EU medical device (MD) regulatory structure has changed from Directives to Regulations to ascer...
The high quality of public health improves not only healthy life expectancy, but also the productivi...
ABSTRACT Introduction: Favoring innovation by making timely medical technology available to people ...
Balancing acceptable risks and early release of products for new treatments in patient care with the...
Imagine a device that could help identify skin cancer by examining moles underneath a patient’s skin...
ObjectivesTo identify the potential opportunities and risks around future UK regulatory reform of me...
Context Recent debates and events have brought into question the effectiveness of existing regulator...
Medical devices have historically been less regulated than their drug and biologic counterparts. A b...
Are FDA premarket trials on new drugs and medical devices excessive and do they inhibit consumer acc...